Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...

Q2 2025 Management View CEO Robert Wessman highlighted strong growth momentum in the first half of the year, citing "strong reorders, successful product launches, development progress and improved ...

Alvotech ( ($ALVO) ) has released its Q2 earnings. Here is a breakdown of the information Alvotech presented to its investors. Alvotech is a ...

Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech’s history in terms of operating cash flows Continued expansion of commercial partnerships for ...

Analysts expect Alvotech to report an earnings per share (EPS) of $-0.11. The announcement from Alvotech is eagerly anticipated, with investors seeking news of surpassing estimates and favorable ...

It's been a mediocre week for Alvotech (NASDAQ:ALVO) shareholders, with the stock dropping 17% to US$9.55 in the week since its latest yearly results. The results don't look great, especially ...

Alvotech has a commercialization partnership with Teva Pharmaceuticals TEVA in the United States. The brand names of AVT04 and AVT02 are Selarsdi and Simlandi, respectively, in the United States.

Alvotech asserts that its biosim is the first-filed copycat equal in strength to the latest version of Humira, which AbbVie markets as a high-concentration, pain-free version of the med.

REYKJAVIK, Iceland--(BUSINESS WIRE)--Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for ...

REYKJAVIK, Iceland-- (BUSINESS WIRE)--Alvotech, a powerful new player in the field of biopharmaceuticals, today announced plans to invest $250 million in the development and manufacturing of a ...